Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

Psoriasis organizations ... patients with lived experience, and information from top institutions. Susan Bard, MD, is a clinical instructor in the department of dermatology at Weill Cornell ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

Join Drs Steven Feldman and Robert Kushner as they discuss the role of dermatologists in treating obesity in conjunction with psoriasis.

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...